Delivery Order SPE2DB24D1107-SPE2DB25FZGC9
- Not listed
- The Defense Logistics Agency awarded a $1,341.81 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Protopam Chloride 1 GM vials, with an ultimate completion date of July 25, 2025. This non-set-aside contract was competitively awarded and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement needs, particularly...
- The U.S. Department of Defense Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $2,900.50 for Protopam Chloride 1 GM vials, with an ultimate completion date of July 22, 2025. This non-set-aside contract was competitively awarded on a firm fixed-price basis. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor supporting federal medical procurement needs across military and veteran healthcare...
- The Defense Logistics Agency awarded a $5,960.39 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Protopam Chloride 1 GM vials, with an ultimate completion date of July 24, 2025. This is a non-set-aside contract, competitively awarded to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued...
- The Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Protopam Chloride 1 GM vials. This competitively awarded, firm fixed-price delivery order has a ceiling value of $2,540.93 and an ultimate completion date of August 4, 2025. The contract will be performed at AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania. As a non-set-aside award, this delivery order was competed among...
- The Defense Logistics Agency Medical Supply Chain awarded a $1,451.96 delivery order to AmerisourceBergen Drug Corp for Protopam Chloride 1 GM vials on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price delivery order was placed with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Protopam Chloride is a cholinesterase reactivator used in medical countermeasures...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of PROTOPAM CHLORIDE 1 GM VIALS, with a ceiling value of $4,292.95 and a period of performance through June 18, 2025. The contract is not set aside and was awarded on June 17, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The award, with a ceiling value of $1,517.25, is for the delivery of PROTOPAM CHLORIDE 1 GM VIALS to support military treatment programs and facilities. It is a firm fixed price delivery order contract with a period of performance through March...
- This is a delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the delivery of PROTOPAM CHLORIDE 1 GM VIALS, a pharmaceutical product, with a ceiling value of $4,222.88 and a completion date of June 10, 2025. The contract is a Firm Fixed Price (FFP) arrangement and is not set aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This is a firm fixed-price delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the supply of PROTOPAM CHLORIDE 1 GM VIALS, a medical product, with an ultimate completion date of July 17, 2025 and a ceiling value of $1,940.88. The contract is not set-aside and was competitively awarded. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on July 29, 2025, valued at $2,451.24 for the supply of Protamine 50 mg/5 mL vials. This competitively awarded, firm fixed-price contract is funded by the Medical Supply Chain, a defense agency component, with a completion date of July 30, 2025. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with the...
- SPE2DB24D1107Indefinite Delivery Contract
- SPE2DB24D1107-SPE2DB25FZGC9Delivery Order
The Defense Logistics Agency awarded a $2,263.89 firm fixed price delivery order to AmerisourceBergen Drug Corp for Protopam Chloride 1 GM vials, with an ultimate completion date of August 1, 2025. This competitive award includes no set-aside designation and represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This delivery order exemplifies AmerisourceBergen's critical role as a pharmaceutical supplier within the Defense Logistics Agency's medical supply chain. The company maintains a $999.99 billion prime IDC with DLA Troop Support Medical through December 2026, which serves as a comprehensive vehicle for supplying pharmaceuticals and medical supplies to support military healthcare programs globally. Protopam Chloride, an antidote used in medical emergencies, represents the type of specialized pharmaceutical commodity that AmerisourceBergen delivers through its expansive federal contract portfolio. The company's demonstrated capability to compete successfully for medical procurement requirements across multiple therapeutic domains and product categories supports its ongoing role as a key federal healthcare vendor.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 7/31/25 |